Basilea reports acceptance for regulatory review of Pfizer’s marketing authorization application for antifungal isavuconazole (...
Basel, Switzerland, August 07, 2020 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the marketing authorization application (MAA) for the antifungal isavuconazole (Cresemba®) for the treatment of patients with mucormycosis, which was submitted …